OIS@AAO
The Argus II transmits images wirelessly to a layer of 60 tiny electrodes on the retina inside the eye, to reverse vision lost as a…
Read MoreParticipant: Michelle Snyder Michelle is currently the CMO at Welltok leading all corporate and product marketing efforts and is an investment and operational advisor to…
Read MoreParticipant: David Parke, MD II Dr. Parke is CEO of the American Academy of Ophthalmology. Prior to assuming this role, Dr. Parke served as president…
Read MoreParticipant: Paul A. Sieving, MD, PhD Dr. Sieving became Director of the National Eye Institute after serving as the Paul R. Lichter Professor of Ophthalmic…
Read MoreParticipants: William J. Link, PhD Prior to Versant, Bill was a general partner at Brentwood Venture Capital. He founded, and served as chairman and CEO…
Read MoreA panel of Wall Street analysts offer their insights on the future performance of the public markets, including ophthalmology stocks at OIS@AAO in Las Vegas.…
Read MoreParticipants: Jim Mazzo James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and…
Read MoreImplandata Ophthalmic Products GmbH (IOP GmbH), located in Hanover/Germany, is destined to transform management of glaucoma patients via a unique solution for early detection of…
Read More[c RetroSense Therapeutics CEO Sean Ainsworth explains how the company’s optogenetic gene therapeutic can impart light sensitivity to cells in the retina, re-sensitizing it to…
Read MoreIBMD is an early-stage medical device company focused in ophthalmology innovations. The company is leading the emerging, non-laser based, precision capsulotomy category through the development…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.